Clinical Trial Update: Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

View source ↗

Summary

This clinical trial update reports outcomes for chronic immune thrombocytopenic purpura patients switched to eltrombopag versus romiplostim.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• Nplate (romiplostim)
• Promacta (eltrombopag)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Immune Thrombocytopenic Purpura | Status: COMPLETED